vegfr tyrosine kinase inhibitor Recently Published Documents

Cell Carcinoma ◽

Renal Cell ◽

Kinase Inhibitor ◽

Clear Cell ◽

Cell Renal Cell Carcinoma ◽

LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial

Annals of Oncology ◽

10.1016/j.annonc.2020.08.2254 ◽

2020 ◽

Vol 31 ◽

pp. S1157 ◽

Cited By ~ 1

Author(s):

Y. Vano ◽

R.T. Elaidi ◽

M. Bennamoun ◽

C.M. Chevreau ◽

D. Borchiellini ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kidney Cancer ◽

Phase Ii ◽

Kinase Inhibitor ◽

BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer

Bulletin du Cancer ◽

10.1016/s0007-4551(20)30283-6 ◽

2020 ◽

Vol 107 (5) ◽

pp. eS22-eS27 ◽

Cited By ~ 4

Author(s):

Nicolas Epaillard ◽

Audrey Simonaggio ◽

Reza Elaidi ◽

Fouzia Azzouz ◽

Elena Braychenko ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kidney Cancer ◽

Kinase Inhibitor ◽

Phase 2 ◽

VEGFR Tyrosine Kinase Inhibitor

10.32388/645sey ◽

2020 ◽

Author(s):

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Non-VEGFR Tyrosine Kinase Inhibitor

10.32388/gnr65l ◽

2020 ◽

Author(s):

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma

Pathology & Oncology Research ◽

10.1007/s12253-017-0323-2 ◽

2017 ◽

Vol 25 (1) ◽

pp. 51-58 ◽

Cited By ~ 3

Author(s):

Heounjeong Go ◽

Mun Jung Kang ◽

Pil-Jong Kim ◽

Jae-Lyun Lee ◽

Ji Y. Park ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Cell Carcinoma ◽

Renal Cell ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endothelial Growth Factor ◽

VEGFR tyrosine kinase inhibitor II (VRI) induced vascular insufficiency in zebrafish as a model for studying vascular toxicity and vascular preservation

Toxicology and Applied Pharmacology ◽

10.1016/j.taap.2014.09.005 ◽

2014 ◽

Vol 280 (3) ◽

pp. 408-420 ◽

Cited By ~ 26

Author(s):

Shang Li ◽

Yuan Ye Dang ◽

Ginny Oi Lam Che ◽

Yiu Wa Kwan ◽

Shun Wan Chan ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Vascular Toxicity ◽

Vascular Insufficiency ◽

Vascular Preservation ◽

RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib

PLoS ONE ◽

10.1371/journal.pone.0066003 ◽

2013 ◽

Vol 8 (6) ◽

pp. e66003 ◽

Cited By ~ 21

Author(s):

James R. Bradford ◽

Matthew Farren ◽

Steve J. Powell ◽

Sarah Runswick ◽

Susie L. Weston ◽

...

Keyword(s):

Tyrosine Kinase ◽

Mrna Expression ◽

Kinase Inhibitor ◽

Rna Seq ◽

Human Tumour ◽

Human Tumour Xenografts ◽

Tumour Xenografts ◽

596 The Effect of Rifampin On the Pharmacokinetics of Tivozanib, a Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor

European Journal of Cancer ◽

10.1016/s0959-8049(12)72393-6 ◽

2012 ◽

Vol 48 ◽

pp. 183 ◽

Cited By ~ 2

Author(s):

M. Cotreau ◽

D. Subic ◽

L. Massmanian ◽

A. Strahs ◽

D. Vargo

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endothelial Growth Factor ◽

Abstract C123: A phase 1 study to evaluate the absorption, metabolism, and excretion of the vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) tivozanib.

10.1158/1535-7163.targ-11-c123 ◽

2011 ◽

Cited By ~ 1

Author(s):

Monette M. Cotreau ◽

Christine Hale ◽

Lindsey Jacobson ◽

Claudine S. Oelke ◽

Andrew L. Strahs ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Kinase Inhibitor ◽

Phase 1 ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Phase 1 Study ◽

Endothelial Growth Factor ◽